Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
ARRAY BIOPHARMA INC (ARRY) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/07/2019 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019"
02/05/2019 8-K Quarterly results
10/30/2018 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019 – Strong launch quarter for BRAFTOVI ® + MEKTOVI ® in U.S. with $14 million in net sales – – European Commission approves BRAFTOVI + MEKTOVI for advanced BRAF-mutant melanoma – – COLUMBUS Phase 3 Trial Overall Survival Results Published in the Lancet Oncology – – Cash, Cash Equivalents and Marketable Securities as of September 30, 2018 were $415 million –"
08/14/2018 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018"
05/09/2018 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018 - June 30, 2018 PDUFA date for encorafenib and binimetinib NDAs in BRAF-mutant melanoma - - Encorafenib and binimetinib combination achieved a median overall survival of 33.6 months in patients with BRAF-mutant melanoma in Phase 3 COLUMBUS trial - - Combination of encorafenib, binimetinib and cetuximab demonstrated an 8 month median progression-free survival in patients with BRAF-mutant colorectal cancer in updated safety lead-in results from Phase 3 BEACON CRC trial - - Cash, Cash Equivalents and Marketable Securities as of March 31, 2018 were $440 million -"
02/06/2018 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018",
"Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial"
10/31/2017 8-K Quarterly results
08/09/2017 8-K Quarterly results
Docs: "First Amendment to Subordinated Convertible Promissory Notes by and between Array BioPharma Inc. and Redmile Biopharma Investments I, L.P. and Redmile Capital Offshore Fund II, Ltd",
"mPFS BICR mPFS Local Review"
05/10/2017 8-K Form 8-K - Current report
02/09/2017 8-K Form 8-K - Current report
11/01/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
05/03/2016 8-K Form 8-K - Current report
02/02/2016 8-K Quarterly results
Docs: "Exhibit 99.1 Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2016"
11/04/2015 8-K Quarterly results
Docs: "Exhibit 99.1 Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2016"
08/03/2015 8-K Quarterly results
Docs: "ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF FISCAL 2015"
05/04/2015 8-K Quarterly results
Docs: "ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL 2015"
02/03/2015 8-K Quarterly results
Docs: "ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2015"
11/04/2014 8-K Quarterly results
Docs: "ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2015"
08/12/2014 8-K Quarterly results
Docs: "ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF FISCAL 2014"
04/29/2014 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2014"
02/04/2014 8-K Quarterly results
Docs: "ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2014 Robust Clinical Data on Filanesib Presented at ASH Supporting Announced Registration Program Randomized Phase 2 Trial of Filanesib in Combination with Kyprolis Enrolling Small Phase 2 Trial with ARRY-797 in Rare Cardiovascular Disease Underway Two New Trials Initiated with ARRY-380 in Metastatic Breast Cancer"
10/31/2013 8-K Form 8-K - Current report
08/07/2013 8-K Form 8-K - Current report
05/06/2013 8-K Form 8-K - Current report
02/04/2013 8-K Quarterly results
Docs: "Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013 MEK162 Phase 3 Trial to Start April 2013 AstraZeneca Announced Selumetinib Potential Phase 3 NSCLC Trial Start in 2013"
10/30/2012 8-K Form 8-K - Current report
08/13/2012 8-K Form 8-K - Current report
04/30/2012 8-K Form 8-K - Current report
01/30/2012 8-K Form 8-K - Current report
10/31/2011 8-K Form 8-K - Current report
08/08/2011 8-K Form 8-K - Current report
05/02/2011 8-K Form 8-K - Current report
01/31/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy